The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
== Production == In 2005, Canadian production was 10.5 million square metres (113 million square feet) (3⁄8 in or 9.5 mm basis) of which 8.78 million square metres (94.5 million square feet) were exported, almost entirely to the United States. In 2014, Romania became the largest OSB-exporting country in Europe, with 28% of the exports going to Russia and 16% to Ukraine.
Insecticides are pesticides used to kill insects. They include ovicides and larvicides used against insect eggs and larvae, respectively. The major use of insecticides is in agriculture, but they are also used in home and garden settings, industrial buildings, for vector control, and control of insect parasites of animals and humans. Acaricides, which kill mites and ticks, are not strictly insecticides, but are usually classified together with insecticides. Some insecticides (including common bug sprays) are effective against other non-insect arthropods as well, such as scorpions, spiders, etc. Insecticides are distinct from insect repellents, which repel but do not kill.
=== Bab–Bar === Stephen Moulton Babcock (1843–1931), American agricultural chemist worked on the "single-grain experiment" Myrtle Bachelder (1908–1997), American chemist noted for work on the Manhattan Project atomic bomb, and for work on metal chemistry Werner Emmanuel Bachmann (1901–1951), American chemist, known for work in steroids and RDX Simone Badal-McCreath (21st century), Jamaican chemist who created prostate and breast cancer cell lines Leo Baekeland (1863–1944), Belgian-American chemist known for invention of bakelite Adolf von Baeyer (1835–1917), German chemist, 1905 Nobel Prize in Chemistry, synthesis of indigo Piero Baglioni (born 1952), Italian chemist known for inorganic and organic colloids Hendrik Willem Bakhuis Roozeboom (1854–1907), Dutch chemist who studied phase behaviour in physical chemistry Alice Ball (1892–1916), American chemist known for inventing an effective injectable treatment for leprosy Emily Balskus (born 1980), American chemist and microbiologist known for work on the human microbiome Zhenan Bao (born 1970), Chinese chemist known for developing technologies with organic field-effect transistors and organic semiconductors Phil S. Baran (born 1977), American chemist known for synthesis, novel reactions and reagents Coral Barbas (PhD 1989), Spanish chemist known for research on metabolomics and integration of chemical data Allen J.
Brown fat or brown adipose tissue (BAT) is a specialized form of adipose tissue important for adaptive thermogenesis in humans and other mammals. BAT can generate heat by "uncoupling" the respiratory chain of oxidative phosphorylation within mitochondria through tissue-specific expression of uncoupling protein 1 (UCP1). BAT is primarily located around the neck and large blood vessels of the thorax, where it may effectively act in heat exchange. BAT is robustly activated upon cold exposure by the release of catecholamines from sympathetic nerves that results in UCP1 activation. Nearly half of the nerves present in adipose tissue are sensory neurons connected to the dorsal root ganglia. BAT activation may also occur in response to overfeeding. UCP1 activity is stimulated by long chain fatty acids that are produced subsequent to β-adrenergic receptor activation. UCP1 is proposed to function as a fatty acid proton symporter, although the exact mechanism has yet to be elucidated. In contrast, UCP1 is inhibited by ATP, ADP, and GTP. Attempts to simulate this process pharmacologically have so far been unsuccessful. Techniques to manipulate the differentiation of "brown fat" could become a mechanism for weight loss therapy in the future, encouraging the growth of tissue with this specialized metabolism without inducing it in other organs. A review on the eventual therapeutic targeting of brown fat to treat human obesity was published by Samuelson and Vidal-Puig in 2020.
== Distribution == Psilocybe authority Gastón Guzmán, in his 1983 monograph on psilocybin mushrooms, considered Psilocybe semilanceata the world's most widespread psilocybin mushroom species, as it has been reported on 18 countries. In Europe, P. semilanceata has a widespread distribution, and is found in Austria, Belarus, Belgium, Bulgaria, the Channel Islands, Czech republic, Denmark, Estonia, the Faroe Islands, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, India, Ireland, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, the United Kingdom and Ukraine. It is generally agreed that the species is native to Europe; Watling has demonstrated that there exists little difference between specimens collected from Spain and Scotland, at both the morphological and genetic level. The mushroom also has a widespread distribution in North America. In Canada it has been collected from British Columbia, New Brunswick, Newfoundland, Nova Scotia, Prince Edward Island, Ontario and Quebec. In the United States, it is most common in the Pacific Northwest, west of the Cascade Mountains, where it fruits abundantly in autumn and early winter; fruiting has also been reported to occur infrequently during spring months. Charles Horton Peck reported the mushroom to occur in New York in the early 20th century, and consequently, much literature published since then has reported the species to be present in the eastern United States.
Sources: en.wikipedia.org
Subsequent studies in 1995 confirmed that the db gene encodes the leptin receptor, and that it is expressed in the hypothalamus, a region of the brain known to regulate the sensation of hunger and body weight.
=== Conservative whip suspension === In May 2019, he had the Conservative Party whip suspended after saying he would vote for the Liberal Democrats, rather than the Conservatives, at the 2019 European Parliament election. On 26 November 2019, in preparation for the 2019 general election, Heseltine said he could not support Boris Johnson because the Prime Minister was pursuing an "utterly disastrous" policy that would make Britain poorer and less influential, and he called on voters to back the Liberal Democrats to deny Johnson a majority in Parliament. In June 2023, following the report by the Commons Privileges Committee, he said that Johnson had lied to parliament. Speaking on Sky News, he said that Johnson had resigned before the Partygate report was published because he "saw it coming", adding "We've had four days of this report and the story doesn't change: Boris Johnson told a pack of lies. Boris Johnson got out from under, he saw it coming, he knew he hadn't a case to defend. So he resigned before the suspension that he feared could be relevant." In July 2024, the Conservatives restored Heseltine's whip.
2020, A. T. Williams, C. R. Muller, A. M. Eaker, D. A. Belcher, C. Bolden-Rush, A. F. Palmer, P. Cabrales, “Polymerized hemoglobin with increased molecular size reduces toxicity in healthy guinea pigs,” ACS Applied Bio Materials Apr 14 3, 5:2976–2985. 2020, A. T. Williams, A. Lucas, C. R. Muller, C. Bolden-Rush, A. F. Palmer, P. Cabrales, “Balance between oxygen transport and blood rheology during resuscitation from hemorrhagic shock with polymerized hemoglobin,” Journal of Applied Physiology Jul 1;129(1):97-107. 2021, C. R. Muller, A. Lucas, V. Courelli, A. T. Williams, F. Dos Santos, C. Cuddington, S. Moses, A. F. Palmer, E. Kistler, P. Cabrales, “Resuscitation from hemorrhagic shock after traumatic brain injury with polymerized hemoglobin,” Scientific Reports Jan 28;11(1):2509. Facilitated oxygen transport Palmer's research focuses on approaches to better improve oxygen storage and transport to cultured cells, especially cells grown in bioreactors. Supporting Publications:
=== Endogenous production and effects === In the 1950s, the endogenous production of psychoactive agents was considered to be a potential explanation for the hallucinatory symptoms of some psychiatric diseases; this is known as the transmethylation hypothesis. Several speculative and yet untested hypotheses suggest that endogenous DMT is produced in the human brain and is involved in certain psychological and neurological states. DMT is naturally occurring in small amounts in rat brains, human cerebrospinal fluid, and other tissues of humans and other mammals. Further, mRNA for the enzyme necessary for the production of DMT, INMT, are expressed in the human cerebral cortex, choroid plexus, and pineal gland, suggesting an endogenous role in the human brain. In 2011, Nicholas Cozzi of the University of Wisconsin School of Medicine and Public Health, and three other researchers, concluded that INMT, an enzyme that is associated with the biosynthesis of DMT and endogenous hallucinogens is present in the non-human primate (rhesus macaque) pineal gland, retinal ganglion neurons, and spinal cord. Neurobiologist Andrew Gallimore suggested in 2013 that while DMT might not have a modern neural function, it may have been an ancestral neuromodulator once secreted in psychedelic concentrations during REM sleep, a function now lost.
Enzymes with a substituted-enzyme mechanism can exist in two states, E and a chemically modified form of the enzyme E*; this modified enzyme is known as an intermediate. In such mechanisms, substrate A binds, changes the enzyme to E* by, for example, transferring a chemical group to the active site, and is then released. Only after the first substrate is released can substrate B bind and react with the modified enzyme, regenerating the unmodified E form. When a set of v by [S] curves (fixed A, varying B) from an enzyme with a substituted-enzyme mechanism are plotted in a Lineweaver–Burk plot, a set of parallel lines will be produced. This is called a secondary plot. Enzymes with substituted-enzyme mechanisms include some oxidoreductases such as thioredoxin peroxidase, transferases such as acylneuraminate cytidylyltransferase and serine proteases such as trypsin and chymotrypsin. Serine proteases are a very common and diverse family of enzymes, including digestive enzymes (trypsin, chymotrypsin, and elastase), several enzymes of the blood clotting cascade, and many others. In these serine proteases, the E* intermediate is an acyl-enzyme species formed by the attack of an active site serine residue on a peptide bond in a protein substrate.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.